Skip to Content
PharmaceuticalsPharmaceuticals
  • Article
  • Open Access

1 December 2025

17 Pages

Rifampicin/Quercetin Nanoemulsions: Co-Encapsulation and In Vitro Biological Assessment Toward Tuberculosis Therapy

,
,
,
,
,
,
,
,
…
1
Programa de Pós-Gradução em Ciências da Saúde, Laboratório de Nanotecnologia, Faculdade de Medicina, Universidade Federal do Rio Grande, Rio Grande 96203-900, Brazil
2
Department of Pharmaceutical Sciences, University of Vienna, 1090 Vienna, Austria
3
Escola de Química de Alimentos, Universidade Federal do Rio Grande, Rio Grande 96203-900, Brazil
4
Laboratório Experimental de Imunofarmacologia, Universidade Federal do Triângulo Mineiro, Uberaba 38025-180, Brazil

Abstract

Background: Tuberculosis (TB) remains a leading cause of global mortality, with 1.25 million deaths reported in 2023. Extended treatment duration contributes to poor patient adherence and treatment failure. Innovative drug delivery platforms are needed to improve therapeutic outcomes. Objective: This study aimed to develop nanoemulsions co-encapsulating quercetin and rifampicin and evaluate their physicochemical properties and in vitro biological activity relevant to TB therapy. Methods: Nanoemulsions (NEs) were prepared via hot solvent diffusion and phase inversion temperature techniques. Physicochemical characterization, stability, anti-inflammatory effects in BEAS-2B cells, and antimycobacterial activity against Mycobacterium tuberculosis H37Rv and resistant strains were assessed in vitro. Results: The quercetin-rifampicin nanoemulsion (QUE-RIF-NE) showed an average size of 24 nm, zeta potential of −27 mV, and drug recovery rates of 77% (quercetin) and 75% (rifampicin). The formulation was stable and non-cytotoxic at 10−8 M, reducing IFN-γ production by half and reactive oxygen species production by almost 75% in BEAS-2B cells. It also exhibited antimycobacterial activity against both susceptible and resistant M. tuberculosis strains (MIC ≤ 0.015 µg/mL). Conclusions: QUE-RIF-NE exhibits promising physicochemical stability and dual anti-inflammatory and antimicrobial activity in vitro, demonstrating potential for optimized pulmonary or systemic TB therapy that integrates both anti-inflammatory and antimicrobial effects.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.